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Medicine and the Community
emerging bacterial resistance.
It is now accepted that there is minimal
benefit of treating patients with self-limiting
conditions such s sore throats, sinusitis,
acute bronchitis and acute otitis media, and
no demonstrated need for antibiotic treat-









Objective:  To evaluate the effectiveness of a community-based and GP-based 
intervention in reducing unnecessary antibiotic prescribing for upper respiratory tract 
infections (URTIs) including sore throats, sinusitis and otitis media.
Design:  Analysis of pharmacy dispensing data in June to October before (2000) and 
after (2001) the intervention, which commenced on 25 June 2001.
ng and participants:  Local consumers, health professionals, the Adelaide 
hern Division of General Practice, the South Australian Government, and the local 
ia in a rural region of South Australia, covering about 2000 square kilometres, with a 
lation of over 20 000.
vention:  Community dissemination of consumer information on antibiotic use for 
s (including a local media campaign) and education of health professionals 
ding sessions with general practitioners at the four practices in the study area) on 
current Australian therapeutic guidelines for antibiotics, and a validated clinical scoring 
system for decision making in managing sore throat.
Main outcome measures:  Total dispensing data from local pharmacies for the months 
of June to October in 2000 and 2001, covering the six antibiotics considered most likely 
to be used for URTIs (amoxycillin, amoxycillin/clavulanic acid, cefaclor, doxycycline, 
erythromycin and roxithromycin).
Results:  The dispensing of the six antibiotics reduced by 32% overall, from 77.1 to 52.9 
defined daily doses per 1000 population per day, with statistically significant reductions 
in the range of 31%–70% for individual antibiotics; there was no reduction for amoxycillin 
with or without clavulanic acid.
Conclusion:  The intervention was associated with reduced dispensing of unnecessary 
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antibiotics for URTIs.n 1
sor
(JEI 999, the Joint Expert Technical Advi-y Committee on Antibiotic ResistanceTACAR) reported that current levels
of antibiotic prescribing raise serious con-
cerns about the indiscriminate use of these
agents — particularly in the primary health
care setting — and subsequent risks of
1
tract infections (URTIs).  Antibiotics can
cause side-effects, and prescribing them
reinforces patients’ belief that antibiotics are
necessary.2
Prescribing antibiotics has been identified
as one of the most uncomfortable prescrib-
ing decisions made by doctors in general
practice.3 Doctors’ perceptions of patient
pressure and diagnostic uncertainty contrib-
ute greatly to the decision-making pro-
cess.4,5
A range of evidence-based strategies have
been shown to significantly reduce the
unnecessary prescribing of antibiotics.
“Educational marketing” techniques
directed towards health care profession-
als,6,7 the use of scoring systems by general
practitioners,8 patient information leaflets
and delayed prescriptions9 have all been
shown to optimise antibiotic prescribing in
primary health care. Parent education has
been considered the single most important
element in reducing oral antibiotic overuse
in children.10
Australia’s National Strategy for the Qual-
ity Use of Medicines11 advocates measures
such as those listed above, and also identi-
fies the need for activities to raise awareness,
develop knowledge and skills, and reinforce
existing behaviours that support quality use
of medicines, recognising that more limited
approaches do not lead to sustained behav-
iour change.
We decided to trial an intervention aimed
at reducing antibiotic prescribing for URTIs
through education programs aimed at pre-
scribers and consumers by using the clinical
sore throat score of McIsaac et al,8 and to
compare antibiotic prescribing during the
winter of 2001 (the intervention period) with
prescribing during the previous winter. This
approach to managing patients with an upper
respiratory tract infection and sore throat has
been shown to be useful in community-based
family practice,12 and could substantially
reduce the unnecessary prescribing of antibi-
otics for these conditions.
METHODS
The study was carried out in part of the
Southern Fleurieu Peninsula of South Aus-
tralia, an area of about 2000 square kilo-
metres with a mixture of rural and beachside
towns. At the time of the study, the area had
a population of over 20 000 with 25 GPs in
four practice locations, and five pharmacies.
The area is about one and a half hours’ drive
from Adelaide, and has been the site of a
Quality Use of Medicines (QUM) initiative
(the QUM Coast) involving local health
professionals and the community, to pro-
mote non-drug options for managing
insomnia.13JA • Volume 182 Number 12 • 20 June 2005 617
MEDICINE  AN D THE  COMMU NITYEthical approval for the study was granted
by the Ethics of Research Committee of the
University of South Australia.
The intervention
Pamphlets were prepared for patients,
highlighting the risks and benefits of anti-
biotic use in managing URTIs in the com-
munity. These were distributed to general
practices, pharmacies, the local hospital,
primary schools, childcare centres, clubs
and the Community Health Service from
25 June to October 2001. An article
appeared in the local community newspa-
per on 12 July.
We conducted education sessions for
GPs in the four practices on the QUM
Coast in late June 2001, with expert clini-
cal input by one of the authors (J T).
Sessions were based on material in the
Therapeutic guidelines: antibiotic,14 and cov-
ered the management of URTIs generally,
and the specific use of the sore throat
scoring system. The separate score sheet
(Box 1) was prepared for use by the doctors
in assessing the possibility of streptococcal
infection as a cause of sore throat, and
provided guidance on the use of antibiot-
ics. In some surgeries, the practice nurses
determined the score with the patient or
their parents before the consultation. This
process facilitated discussions with the
patient on diagnosis and treatment
options, raising general awareness of the
broader issues of antibiotic use for URTIs.
The antibiotics
An assessment was made of the antibiotics
most likely to be prescribed for URTIs. The
Therapeutic guidelines: antibiotic14 recom-
mended penicillin V or roxithromycin for
sore throat, amoxycillin, cefaclor, doxycy-
cline or amoxycillin/clavulanic acid for
sinusitis, and amoxycillin, amoxycillin/cla-
vulanic acid or cefaclor for otitis media.
Erythromycin was recommended for pertus-
sis. Pharmaceutical Benefits Scheme dis-
pensing data for 2000 showed amoxycillin
(4 485 000 prescriptions), roxithromycin
(2 549 000), amoxycillin/clavulanic acid
(2 516 000), cefaclor (1 941 000), doxy-
cyline (1 764 000), and erythromycin
(1024000) to be the six most commonly
prescribed antibiotics overall.15 There were
686 000 prescriptions for penicillin V in the
same period.
Data analysis
At the end of the intervention, total dis-
pensing data (including non-subsidised
medicines) related to the prescribing of the
six antibiotics were collected from the five
pharmacies in the area for the period 1
June to 31 October in the years 2000 and
2001. Data were entered into an Access
database16 and transferred to SPSS17 for
analysis and an Excel18 spreadsheet for
reporting. Dispensing rates were reported
as defined daily doses per 1000 population
per day.
Demographic data were obtained for the
project region and for the Australian popu-
lation from the Australian Bureau of Statis-
tics 2001 census.19
RESULTS
A total of 5660 pamphlets were distributed
during the intervention period. Initially,
1000 copies of the clinical sore throat score
sheet were distributed to GP practices, but
demand for additional copies resulted in a
further 1600 being distributed.
Population demographic data (Box 2)
showed a greater percentage of people over
the age of 50 and fewer under the age of 30
in the study area compared with the Austral-
ian population.
Box 3 shows dispensing data and the
percentage change in total dispensing
1 Clinical score to reduce unnecessary antibiotic use in patients with sore throat8
Reprinted from CMAJ 13 Jan 19988 by permission of the Canadian Medical Association.
2 Population demographic characteristics for age and sex19
Project region Australia
Age (years) Male Female Total Male Female Total
0–14 8.4% 8.0% 16.4% 10.6% 10.0% 20.6%
15–29 6.2% 5.8% 12.1% 10.3% 10.1% 20.5%
30–49 11.5% 12.1% 23.5% 14.5% 15.0% 29.5%
50–64 9.6% 11.0% 20.7% 8.0% 7.9% 15.9%
65+ 12.5% 14.4% 26.9% 5.5% 7.0% 12.5%
Overseas visitors — — 0.4% — — 1.1%618 MJA • Volume 182 Number 12 • 20 June 2005
MEDICINE  AN D THE  COMMU NITYbetween the preproject and project periods
for each drug. There was an overall reduc-
tion in dispensing between these periods of
32%, and this was statistically significant
(Mann–Whitney U, < 1; P < 0.01). Individu-
ally, there was a statistically significant
change in dispensing between the preproject
and project periods (P < 0.01) for each anti-
biotic except amoxycillin and amoxycillin/
clavulanic acid.
Doxycycline is used for URTIs, but also
for acne, bronchiectasis, pelvic inflamma-
tory disease and urethritis. Under the
assumption that packs of seven tablets or
capsules were being used for URTIs and
larger packs for chronic conditions, we
assessed the change in dispensing volume
for the small pack sizes separately. This
showed a statistically significant 49%
reduction in dispensing volume (Mann–
Whitney U, < 1; P < 0.01); this was a larger
reduction than the 31% decrease for all
pack sizes of doxycycline.
DISCUSSION
After the intervention, there was a statisti-
cally significant and substantial reduction in
the dispensing of nearly all of the antibiotics
considered most likely to be used for URTIs.
While reductions in dispensing could reflect
general reductions in antibiotic use for all
indications in the study region, or causes
other than the intervention, at least some of
the decrease was likely to be a direct conse-
quence of the intervention.
Dispensing data for total antibiotics (Box
3) suggest an association with a winter
illness, such as URTI, raising confidence that
the antibiotics are being used for such a
condition. Also, there was a greater decrease
in dispensing of the small packs of doxycy-
cline, suggesting a stronger impact of the
intervention on the pack size most likely to
have been prescribed for URTIs.
State and national trends for the selected
antibiotics (9% and 6% reductions, respec-
tively)20 were not statistically significant:
(Mann–Whitney U, 8 and 7; P = 0.42 and
P = 0.31, respectively), so there was a sub-
stantially greater impact in the study region.
If the state and national trends can be taken
as indicative of the impact of the nation-
wide National Prescribing Service (NPS)
campaigns at the time,21,22 it could be inter-
preted that the QUM Coast intervention
substantially enhanced their impact.
The intervention had no effect on the
prescribing of amoxycillin, with or without
clavulanic acid. It may be that the NPS
thrust to reduce prescribing of amoxycillin
for URTIs had the desired effect, and that
there was no further room for improvement.
The NPS reported that the prescribing of
amoxycillin declined substantially before
the year 2000.21 It is also possible that by
the time of the intervention, perhaps as a
consequence of NPS campaigns, amoxycillin
was mostly being prescribed for other indi-
cations so the impact of the intervention
might not have been measurable for this
antibiotic.
The decision to use complete dispensing
data, collected from local pharmacy dis-
pensing computer systems, rather than rely-
ing on data from the PBS, was based on an
assessment of local dispensing data before
the study, which showed that only 60%–
65% of antibiotic prescriptions in the region
were eligible for subsidy under the PBS
(unpublished). However, we found a lack of
consistency between pharmacy software sys-
tems and their ability to generate reports in a
convenient way, which would limit the abil-
ity to conduct a larger evaluation without
committing significant resources to this
method of data collection.
There were some limitations to our study.
We collected prescription data for all antibi-
otic use and not just for prescriptions writ-
ten for URTIs. Indeed, the size of the
reduction in overall prescribing was greater
than anticipated from other studies, and
suggests that there may have been an effect
on reducing unnecessary prescribing for
other indications. We did not attempt to
ascertain whether there was a reduction in
presentations with respiratory tract infec-
tions at the general practices. It is possible
that such a reduction may have contributed
to the fall in prescriptions, although state-
wide epidemiological data on viral respira-
tory infections, which tend to drive antibi-
otic prescribing, show there were more
influenza and other respiratory illnesses
during the project year than the preproject
year.23
3 Dispensing volume of the six antibiotics most likely to be prescribed for upper 
respiratory tract infections for the preproject (1 June to 31 October 2000) and 
project (1 June to 31 October 2001) periods
Volume of drug dispensed (defined daily doses per 1000 population per day)




Preproject 2.2 2.9 3.4 3.5 2.9 14.8 + 2.8%
Project 2.6 2.7 3.1 3.6 3.3 15.2
Amoxycillin/clavulanic acid
Preproject 2.1 2.6 3.1 3.4 2.0 13.2 − 8.1%
Project 2.2 2.3 2.4 2.6 2.6 12.2
Cefaclor
Preproject 0.6 0.8 1.1 1.1 0.6 4.2 − 57.1%
Project 0.5 0.3 0.3 0.4 0.3 1.8
Doxycycline (all pack sizes)
Preproject 2.8 3.7 3.4 2.9 2.8 15.6 − 31.4%
Project 2.2 2.4 2.3 2.2 1.7 10.7
Erythromycin
Preproject 1.4 2.5 2.7 2.1 1.5 10.2 − 69.6%
Project 0.6 0.6 0.6 0.7 0.6 3.1
Roxithromycin
Preproject 3.1 4.5 3.8 4.4 3.0 18.7 − 30.8%
Project 2.2 2.6 2.4 2.7 3.0 12.9
Total antibiotics
Preproject 12.5 16.6 17.5 17.3 12.9 77.1 − 31.5%
Project 9.6 10.3 10.5 11.5 11.0 52.9
Doxycycline (small pack sizes)
Preproject 1.5 1.5 1.4 1.2 1.1 6.8 − 49.1%
Project 0.8 0.9 0.6 0.7 0.5 3.4MJA • Volume 182 Number 12 • 20 June 2005 619
MEDICINE  AN D THE COMMU NITYThere was an older age profile for the
population within the study region com-
pared with Australian population figures,
and this might limit the generalisability of
the findings. However, it might be argued
that because the target population was local
children and their parents, the potential to
influence prescribing in other areas where
there are higher percentages of children is
even greater.
Finally, the study was not designed to
measure the sustainability of the interven-
tion. Short-term effects have been seen with
a variety of interventions to reduce unneces-
sary prescribing for URTIs, but sustainable
long-term reductions are being sought.24
In conclusion, we found that a commu-
nity-based approach, involving GP educa-
tion and the distribution of educational
materials throughout the community was
well received and successful in reducing
dispensing of antibiotics for URTIs.
Based on the results of this project, the
intervention has been rolled out across the
state in conjunction with the Divisions of
General Practice, the Department of Educa-
tion and Children’s Services, and private
schools, and an evaluation is planned for
2005 which will provide an opportunity to
assess the sustainability of the program on
the QUM Coast.
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